INTRODUCTION

Neuroendocrine carcinomas are rare malignant tumors which, in most of cases, are located in the lungs and gastrointestinal tract. Primary location of such tumors in the breast is extremely rare, corresponding to less than 0.1% of all breast tumors\(^1\)\(^2\).

Most published studies about neuroendocrine breast carcinoma emphasize anatomopathological findings, with scarce reference to imaging findings\(^3\)\(^4\).

The present report describes mammographic, sonographic and magnetic resonance imaging (MRI) findings of a case of asymptomatic, primary neuroendocrine breast carcinoma in a 75-year-old woman.

CASE REPORT

Mammography detected an ovoid, well defined mass with medium density in the upper-inner quadrant of the left breast in an asymptomatic 75-year-old woman. No associated microcalcifications were observed (Figure 1). At ultrasonography, the mass corresponded to a hypoechoic, morphologically irregular and ill defined, solid nodule, with no al-
Figure 2. Ultrasonography demonstrated a solid hypoechoic mass with ill defined contours, without any alteration of posterior echoes, measuring 19 mm in its largest diameter.

The patient underwent preoperative breast MRI (Figure 4) which confirmed the presence of a hypointense, irregular lesion with 20 mm in diameter on T2-weighted sequences, with peripheral ring-enhancement after intravenous gadolinium injection, and kinetic curve demonstrating early intense contrast uptake, followed by washout. Additionally, another adjacent, small nodular focus measuring 5 mm was observed, with comparable features.

In order to rule out a possible extramammary location of neuroendocrine carcinoma, thoracic, abdominal and pelvic computed tomography (CT) was performed, but no other lesion was detected.

The patient underwent conservative surgery and the anatomopathological analysis of the surgical specimen confirmed the diagnosis of a moderately differentiated, multifocal neuroendocrine breast carcinoma.

DISCUSSION

Neuroendocrine carcinoma primarily located in the breast is an extremely rare entity. Although exact data on its incidence is not available yet, a series developed by Günhan-
Bilgen et al. with 1,845 proved cases of breast tumors reports an incidence as low as 0.27%. Such a tumor presents specific morphological characteristics, expressing neuroendocrine markers on a high percentage (> 50%) of the cells. Neuron specific enolase, synaptophysin and chromogranin are generally utilized as markers; the first one is considered as less specific. In 2003, the World Health Organization classified neuroendocrine breast carcinomas into three subtypes, as follows: solid, small cell and large cell carcinomas. However, in a recent revision undertaken in 2012, neuroendocrine tumors, included in the class of rare epithelial tumors, were subdivided into well differentiated neuroendocrine tumors, poorly differentiated neuroendocrine carcinomas (small cell carcinomas), and carcinomas with neuroendocrine differentiation. In the present case, the tumor was positive for the three neuroendocrine markers, with solid histological subtype and carcinoid-like pattern (the assessment was made prior to the 2012 revision).

The cases of primary neuroendocrine breast carcinoma described in the literature refer mostly to women in the age range between 40 and 70 years, and there are some few cases described in male individuals. The diagnosis of primary neuroendocrine breast carcinoma can only be made if an extramammary location is ruled out or an in situ component is demonstrated. In the present case, although an in situ component has not been demonstrated, other locations, namely pulmonary or intestinal, were ruled out at CT.

Neuroendocrine carcinomas do not present any particular imaging finding and, in many cases, the findings are comparable to the ones of other types of breast tumors. On mammography, as described by Ogawa et al., such tumors may present as well circumscribed lesions, with no associated microcalcifications, mimicking benign lesions. Such findings are in agreement with the ones observed in the present case, where the lesion corresponded to a well defined mass of medium density and with no associated microcalcifications. On ultrasonography, such tumors may present as either morphologically irregular solid lesions or lesions with a cystic component, with ill defined margins and increased vascularization. Also, in the present case, ultrasonography revealed the presence of a hypoechoicogenic mass with irregular morphology and ill defined contours, with no cystic component. MRI demonstrated, like in other cases described in the literature, the presence of an irregular lesion with early, intense, ring-enhancement, with morphological and kinetic characteristics of contrast uptake consistent with malignancy.

Thus, despite the rarity of neuroendocrine carcinomas, with nonspecific imaging findings, such tumors should be included in the differential diagnosis of a nodular lesion with no associated microcalcifications on mammography and sonographically corresponding to a hypoechoicogenic mass with microlobulated or irregular contours.

REFERENCES
1. Ogawa H, Nishio A, Satake H, et al. Neuroendocrine tumor in the breast. Radiat Med. 2008;26:28–32.
2. Menéndez P, García E, Babadán L, et al. Primary neuroendocrine breast carcinoma. Clin Breast Cancer. 2012;12:300–3.
3. Kinoshita S, Hirano A, Komine K, et al. Primary small-cell neuroendocrine carcinoma of the breast: report of a case. Surg Today. 2008;38:734–8.
4. Fujimoto Y, Yagyu R, Murase K, et al. A case of solid neuroendocrine carcinoma of the breast in a 40-year-old woman. Breast Cancer. 2007;14:250–3.
5. Günhan-Bilgen I, Zekioglu O, Ustün EE, et al. Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings. Eur Radiol. 2003;13:788–93.
6. Nozoe T, Sueishi K, Mori E, et al. Primary neuroendocrine carcinoma of the breast: report of a case. Surg Today. 2011;41:829–31.
7. Kin JW, Woo OH, Cho KR, et al. Primary large cell neuroendocrine carcinoma of the breast: radiologic and pathologic findings. J Korean Med Sci. 2008;23:1118–20.
8. Gobbi H. Classificação dos tumores da mama: atualização baseada na nova classificação da Organização Mundial da Saúde de 2012. J Bras Patol Med Lab. 2012;48:463–74.
9. Graça S, Esteves J, Costa S, et al. Neuroendocrine breast cancer. BMJ Case Rep. 2012 Aug 13;2012.
10. Alkaied H, Harris K, Azab B, et al. Primary neuroendocrine breast cancer, how much do we know so far? Med Oncol. 2012;29:2613–8.